亿帆医药：上半年创新药销售收入同比增长169.57%

Core Viewpoint - The company reported a significant increase in sales revenue from innovative drugs, which rose by 169.57% year-on-year, contributing to a substantial improvement in the non-GAAP profit margin [1] Group 1: Financial Performance - The sales revenue from innovative drugs reached a notable growth of 169.57% compared to the previous year, indicating strong market demand and effective commercialization strategies [1] - The high-margin business segment's proportion increased rapidly, becoming a key driver for the substantial rise in the company's non-GAAP profit margin during the reporting period [1] Group 2: Product Development - The company is advancing the commercialization of its key product, Yilishu, which is its first independently developed Class I macromolecule innovative biopharmaceutical [1] - Yilishu has completed its first shipment to the U.S. market, with a market terminal price of $4,600 per unit, marking the product's official entry into the U.S. market [1]